Nytt kursmål fra DNB, 80 - 110.,- La full analyse på insider tråden.
Resetting expectations
The management team did a solid job when it reset the
expectations and timelines for Betalutin’s development
plan. Management made new commitments to update
the market about countries approved for the trial and
number of active sites at the quarterly reports.
Investors have sought that type of information for a
long time. Looking forward, we believe the risks in the
development plan are lower than initially anticipated
and with boosted confidence in the plan for Betalutin,
we have increased our target price to NOK110
(NOK80). We reiterate our BUY recommendation.